Infectious Diseases in Critical Care Medicine

30. Westphal J, Jehl F, Vetter D. Pharmacological, toxicologic, and microbiological considerations in the
    choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver. Clin
    Infect Dis 1994; 18:324–335.


31. Rimola A, Salmero ́n JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of
    spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study.
    Hepatology 1995; 21:674–679.


32. Franca AVC, Giordano HM, Seva-Pereira T, et al. Five days of ceftriaxone to treat spontaneous
    bacterial peritonitis in cirrhotic patients. J Gastroenterol 2002; 37:119–122.


33. Ariza J, Xiol X, Esteve M, et al. Aztreonam vs. cefotaxime in the treatment of gram-negative
    spontaneous peritonitis in cirrhotic patients. Hepatology 1991; 14:91–98.


34. Go ́mez-Jimenez J, Ribera E, Gasser I, et al. Randomized trial comparing ceftriaxone with cefonicid for
    treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrob Agents Chemother
    1993; 37:1587–1592.


35. Grange JD, Amiot X, Grange V, et al. Amoxicillin-clavulanic acid therapy of spontaneous bacterial
    peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology 1990; 11:360–364.


36. Ricart E, Soriano G, Novella MT, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of
    bacterial infections in cirrhotic patients. J Hepatol 2000; 32:596–602.


37. Terg R, Cobas S, Fassio E, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the
    treatment of spontaneous bacterial peritonitis: results of a multicenter randomized study. J Hepatol
    2000; 33:564–569.


38. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus
    intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroentrolgy 1996; 111:1011–1107.


39. Rimola A, Garcia-Tsao G, Navasa M, et al. the International Ascites Club. Diagnosis, treatment and
    prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32:142–153.


40. Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotics.
    The Cochrane Database of Systematic Reviews 2001; 3:CD002232,1–16.


41. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in
    cirrhosis: incidence, clinical course, predictive factors, and prognosis. Hepatology 1994; 20:1495–1501.


42. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in
    patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403–409.


43. Tito ́L, Rimola A, Gine ́s P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency
    and predictive factors. Hepatology 1988; 8:27–31.


44. Singh N, Gayowski T. Yu VL, et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous
    bacterial peritonitis in cirrhosis. Ann Intern Med 1995; 122:595–598.


45. Gine ́s P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence
    in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12:716–724.


46. Ferna ́ndez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis
    delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818–824.


47. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial
    peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48:774–779.


48. Campillo B, Dupeyron C, Richardet J, et al. Epidemiology of severe hospital-acquired infections in
    patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998;
    26:1066–1070.


49. Ortiz J, Vila MC, Soriano G, et al. Infections caused byEscherichia coliresistant to norfloxacin in
    hospitalized cirrhotic patients. Hepatology 1999; 29:1064–1069.


50. Rabinovitz M, Prieto M, Gavaler JS, et al. Bacteriuria in patients with cirrhosis. J Hepatol 1992; 16:73–76.


51. Kuo CH, Changchien CS, Yang CY, et al. Bacteremia in patients with cirrhosis of the liver. Liver 1991;
    11:334–339.


52. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death. Analysis of the
    national hospital discharge summary. Chest 2003; 124:1016–1020.


53. Barnes PF, Arevalo C, Chan LS, et al. A prospective evaluation of bacteremic patients with chronic
    liver disease. Hepatology 1988; 8:1099–1103.


54. Thulstrup AM, Sørensen HT, Schønheyder HC, et al. Population-based study of the risk and short-
    term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000; 31:1357–1361.


55. Selby WS, Norton ID, Pokorny CS, et al. Bacteremia and bacterascites after endoscopic sclerotherapy
    for bleeding esophageal varices and prevention by intravenous cefotaxime: a randomized trial.
    Gastrointest Endosc 1994; 40:680–684.


56. Rolando N, Gimson A, Philpott-Howard J, et al. Infectious sequelae after endoscopic sclerotherapy of
    oesophageal varices: role of antibioitic prophylaxis. J Hepatol 1993; 18:290–294.


57. Kulkarni SG, Parikh SS, Dhawan PS, et al. High frequency of bacteremia with endoscopic treatment of
    esophageal varices in advanced cirrhosis. Indian J Gastroenterol 1999; 18:143–145.

348 Preheim